Kahr medical is a company that develops a novel drug platform designed to offer immuno-oncology therapies. Its platform uses the Dual Signaling Proteins (DSP) technology for the development of third-generation biological drugs having fusion-protein molecules for the treatment of multiple types of cancer, enabling doctors to manage the immune system and target complex biological processes within the immune system.